Physician profile
Carol E Calabrese
NPI 1972569671
$1,122.74
in general payments reported to CMS, 2019-2025
16 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $12.23 · 2021: $44.32 · 2022: $322 · 2023: $206 · 2024: $128 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $308.60 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Pfizer INC. | $226.64 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $144.70 | 2025 | Neffy |
| Sanofi Pasteur INC. | $136.37 | 2023-2024 | |
| Cranial Technologies, INC | $73.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.81 | 2019-2023 | Vaxneuvance, Rotateq, Vaxelis |
| Tris Pharma INC | $42.63 | 2022-2023 | Dyanavel Xr |
| Seqirus USA INC | $19.84 | 2023 | Flucelvax Quadrivalent |
| Hologic Sales and Service, LLC | $16.91 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.13 | 2019 | |
| Cognoa, INC. | $14.85 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.47 | 2021 | |
| Shire North American Group INC | $14.30 | 2019 | |
| Sobi, INC | $14.28 | 2023 | |
| Genentech USA, INC. | $13.52 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.